FGEN vs WY · rev $29.6M vs P/E 43, rev $3.59B
FibroGen Inc (FGEN) versus Weyerhaeuser Company (WY) — a side-by-side from cached financials, not a winner call.
FibroGen Inc (FGEN) is a biotechnology company listed on NASDAQ.
Weyerhaeuser Company (WY) is a reit - specialty company listed on NYSE.
Latest reported FGEN revenue for 2024-12-31 was $29.6M. Net income was -$47.6M. Revenue was down 36.7% from 2023-12-31 to 2024-12-31. FGEN currently screens at market cap $39.3M.
Latest reported WY revenue for 2026-06-30 was $3.59B. Net income was $318.0M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
FGEN currently screens at market cap $39.3M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
Not investment advice. Open the FGEN and WY stock pages for the full models.
Not investment advice.